|
| Author, reference | Model | Drug | Main findings |
|
| Maedler et al., 2004 [65] | Glucotoxicity- and lipotoxicity-induced injury in human beta cells | Recombinant IL-1 receptor antagonist (anakinra) | Increased levels of insulin, protection against glucose-induced beta-cell apoptosis |
| Ehses et al., 2009 [61] | T2D GK rats | IL-1 receptor antagonist | Reduced islet immune cell infiltration, decreased glucose levels, increased insulin levels |
| Böni-Schnetzler et al., 2009 [64] | Human islet cultures from T2D patients | Recombinant IL-1 receptor antagonist (anakinra) | Reversal of beta-cell dysfunction |
| Westwell-Roper et al., 2015 [62] | Lean and obese male mice | IL-1 receptor antagonist | Improved glucose tolerance and reduced plasma proinsulin: insulin ratio, no effect on insulin sensitivity, reduced severity, and prevalence of islet amyloid deposition |
| Sauter et al., 2015 [63] | C57BL/6N mice | Anti-IL-1β antibody | Reduced beta-cell apoptosis, restored insulin secretion, and improved glycemia |
| Solt et al., 2015 [51] | NOD mice | Selective inverse agonist of RORα/β | Reduced incidence of diabetes, reduced insulitis, and proinflammatory cytokine expression |
| Mohamed et al., 2016 [53] | STZ-induced-diabetic mice, db/db mice and Ins2Akita mutant mice | Low-dose IL-17A administration | Decreased albuminuria and renal damage |
| Qiu et al., 2017 [57] | High glucose (HG)-treated rat Müller cell line (rMC-1) | Anti-IL-17A or anti-IL-17RA | Improved retinal Müller cell dysfunction, reduced vascular leukostasis and vascular leakage, reduced tight junction protein downregulation, and ganglion cell apoptosis in the retina |
| Lee et al., 2018 [58] | Obese diabetic mouse wounds | Anti-IL-17 and anti-IL-23 blocking antibodies | Accelerated diabetic wound healing through alteration of macrophage polarization |
| Ma et al., 2019 [54] | Streptozotocin-induced diabetic nephropathy through IL-17 knockout mice | Monoclonal anti-IL-17 antibody | Prevention of progression of diabetic nephropathy, reduced albuminuria, glomerular damage, macrophage accumulation, and renal fibrosis |
| Lavoz et al., 2019 [47] | BTBR Ob/Ob (leptin deficiency mutation) mice with diabetic nephropathy | IL-17A neutralizing antibody | Ameliorated renal dysfunction and reduced disease progression |
| Orejudo et al., 2019 [55] | C57BL/6 mice | IL17A neutralizing antibody | Reduced kidney inflammatory cell infiltrates and chemokine overexpression |
| Findeisen et al., 2019 [66] | Mice fed a high-fat diet and leptin receptor deficient mice models | gp130 ligand IC7Fc | Improved glucose tolerance and hyperglycemia by increase in plasma insulin and C-peptide levels, preserved skeletal muscle mass |
|
